Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Rhea-AI Summary

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) presents data on EDG-7500 at ACC.24, highlighting its beneficial effects in preventing diastolic dysfunction in non-obstructive hypertrophic cardiomyopathy. EDG-7500, a first-in-class oral cardiac sarcomere modulator, shows promising results in preclinical studies, offering a novel therapy for HCM patients with options.

– Presentation highlights beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy (HCM) –

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The conference will take place in Atlanta, GA at the Georgia World Congress Center from April 6-8, 2024.

“EDG-7500 is a novel investigational therapy for the treatment of HCM with a differentiated mechanism of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. “Importantly, in our preclinical studies, EDG-7500 has shown potent gradient reduction, normalization of hyperdynamic contractility, and significant improvements in ventricular filling. At ACC, data supporting beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive HCM will be presented and discussed. Despite recent therapeutic advances in obstructive HCM, patients with symptomatic non-obstructive disease have limited options.”

Edgewise Presentation at ACC.24:

Session: From the bench to the bedside: Advances in heart failure & cardiomyopathies

Poster Presentation: 1087-05 - Chronic Treatment with the Novel Sarcomere Modulator EDG-7500 Improves Left Ventricular Distensibility and Cardiac Output Recruitment Under Stress in a Mini-pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy

Presenter: Marc Evanchik, Vice President Discovery and Translational Pharmacology, Edgewise Therapeutics

Date: Sunday, April 7, 2024, 3:15 – 3:25 pm ET

The scientific poster will be available on the Edgewise website after it is presented.

About EDG-7500 for HCM

EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. Preclinical data in models of both obstructed and non-obstructed HCM suggest the ability to drive a broadly effective clinical response at a low risk of decreasing left ventricular ejection fraction below normal at all doses tested. Due to EDG-7500’s self-limiting mechanism on systolic contraction, the Company plans to investigate fixed-dose regimens of EDG-7500, thus potentially eliminating the echo-mediated dose titration and intense follow-up requirements of current therapy. The Company is advancing a randomized, placebo-controlled, single and multiple ascending dose Phase 1 trial evaluating safety, tolerability, PK and pharmacodynamics in healthy adults. To learn more about this trial (NCT06011317), go to clinicaltrials.gov.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of first-in-class therapeutics. EDG-5506 is an orally administered skeletal myosin inhibitor in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel cardiac sarcomere modulator for the treatment of HCM and other disorders of cardiac diastolic dysfunction. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328046868/en/

Edgewise Contacts

Investors:

Michael Carruthers, Chief Financial Officer

ir@edgewisetx.com



Media:

Maureen Franco, VP Corporate Communications

media@edgewisetx.com

Source: Edgewise Therapeutics

FAQ

What is the ticker symbol for Edgewise Therapeutics, Inc.?

The ticker symbol for Edgewise Therapeutics, Inc. is EWTX.

What is the focus of the presentation at ACC.24 by Edgewise Therapeutics?

The presentation highlights the beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy.

When and where will the American College of Cardiology's Annual Scientific Session (ACC.24) take place?

ACC.24 will take place in Atlanta, GA at the Georgia World Congress Center from April 6-8, 2024.

Who will present the data on EDG-7500 at ACC.24?

The data on EDG-7500 will be presented by Marc Evanchik, Vice President Discovery and Translational Pharmacology at Edgewise Therapeutics.

What are some improvements shown by EDG-7500 in preclinical studies?

EDG-7500 has shown potent gradient reduction, normalization of hyperdynamic contractility, and significant improvements in ventricular filling in preclinical studies.